Feasibility of Neoadjuvant Immune Checkpoint Blockade for Resectable Diffuse Pleural Mesothelioma Along Potential of ctDNA Analyses to Detect Residual Disease By Ogkologos - September 22, 2025 563 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a phase II study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Opdualag Becomes First FDA-Approved Immunotherapy to Target LAG-3 April 6, 2022 Patients less likely to rate cancer care as ‘very good’ during... August 4, 2021 ESMO Announces Winners of its Awards 2020 [ESMO Press Release] August 25, 2020 Research Says That Your Birth Order Can Shape Your Personality April 4, 2019 Load more HOT NEWS Health inequalities: Why do people smoke if they know it’s bad... Cetuximab Outperforms Durvalumab for Head and Neck Cancer When Cisplatin Isn’t... “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain... Answers to Your Questions About the COVID-19 Vaccine
